Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Breaks Record On Approvals

FDA Reports 1,171 Generic Drug Approvals In Fiscal 2019

Executive Summary

As the FDA breaks its record for generic drug approvals in fiscal year 2019, it emphasizes the importance of consumer confidence in the safety and quality of approved generics. 

You may also be interested in...



FDA Generic Approvals Peak In April

The April total is the highest monthly total in seven months, but only a few are first generics. Approval volume might continue rising if FDA does not find too many applications requiring in-person inspections, which were largely postponed as part of coronavirus containment measures, Robert Pollock, senior advisor and outside director to the board at Lachman Consultants, said.

US Approvals Off To A Slow Start

US FDA reports another low tally of full approvals in October, but stakeholders are not worried given the agency's history of record-breaking totals year over year.

AAM Commits To Work With FDA On Shortages

The AAM has commended the FDA’s efforts on identifying the root causes of drug shortages in 2019 and has committed to work with the agency in pursuit of a “healthy, sustainable market for safe, effective and affordable medicines for patients.”

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB149291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel